Company is awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health and certified as a Great Place to Work^®

Recognition underscores commitment to mission-driven culture and exceptional support for employee mental health

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, has earned two prestigious workplace honors in 2025, reinforcing its commitment to employee well-being and a strong, values-driven culture. For the third consecutive year, Vistagen received Mental Health America’s Platinum Bell Seal for Workplace Mental Health, their highest distinction for mental health standards in the workplace. The company has also been certified as a Great Place to Work^® for the second year in a row.

"These recognitions are an independent and meaningful reflection of our ongoing efforts to foster a workplace where our team feels supported, valued, and inspired,” said Trisha Fitzmaurice, Senior Vice President of Human Resources at Vistagen. “Internally, they affirm that our people-first approach is impactful. Externally, they show our commitment to setting a high standard for prioritizing mental health and workplace culture across the industry.”

The Platinum Bell Seal is the highest recognition awarded by Mental Health America, the nation’s leading nonprofit dedicated to promoting mental well-being. Vistagen underwent a rigorous evaluation of its policies and practices in four areas: workplace culture, benefits, compliance, and wellness programs. According to Mental Health America, only two in five employers who were assessed met the standards for Bell Seal certification, and achieving a platinum designation – awarded only to those scoring between 92% and 100% – reflects the highest standards of workplace mental health support and leadership.

The Great Place to Work^® Certification™ is based on employee feedback about their experiences working at Vistagen. According to Great Place to Work^®, employees at certified workplaces are 93% more likely to look forward to coming to work and are twice as likely to feel that they are paid fairly, earn a fair share of the company's profits, and have a fair chance at promotion.

About Vistagen

Headquartered in South San Francisco, CA, Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to rapidly activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. They are designed to achieve therapeutic benefits without requiring absorption into the blood or uptake into the brain, giving them the potential to be a safer alternative to other pharmacological options if successfully developed and approved.

Vistagen is passionate about developing transformative treatment options to improve the lives of individuals underserved by the current standard of care for multiple highly prevalent indications, including social anxiety disorder, major depressive disorder, and multiple women’s health conditions, including vasomotor symptoms (hot flashes) associated with menopause. Connect at www.Vistagen.com.

Forward-looking Statements

This press release contains certain forward-looking statements made by Vistagen within the meaning of the federal securities laws. These forward-looking statements involve known and unknown risks that are difficult to predict and include all matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “project,” “outlook,” “strategy,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “strive,” “goal,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by Vistagen and its management, are inherently uncertain. These uncertainties, risks, and other matters are more fully discussed in the section entitled “Risk Factors” in filings Vistagen makes with the U.S. Securities and Exchange Commission (SEC) from time to time. Vistagen’s SEC filings are available on the SEC’s website at www.sec.gov. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing Vistagen’s views as of any subsequent date. Vistagen explicitly disclaims any obligation to update any forward-looking statements other than as may be required by law. If Vistagen does update one or more forward-looking statements, no inference should be made that Vistagen will make additional updates with respect to those or other forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250715115187/en/